TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02809924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based just-in-time training
Description: Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video training
Description: Video describing endotracheal intubation
Study: NCT02164643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutemetamol (18F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Study: NCT01990573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3mg/kg IV methadone HCl
Description: Group I will receive 0.3mg/kg IV methadone HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4mg/kg IV methadon HCl
Description: Group II will receive 0.4mg/kg IV methadone HCl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control no methadone
Description: The control group will not receive methadone.
Study: NCT02377492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressins
Description: Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Study: NCT00886366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses a-h suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single doses suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single doses suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single doses suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses a-d suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6714
Description: Oral single doses d and g suspension
Study: NCT03970759

Intervention type: DRUG
Intervention: Stannous Fluoride Dentifrice
Description: Experimental stannous fluoride (0.454%) dentifrice

Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing (0.3%) triclosan.

Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study: NCT01836146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN™ Renal Artery Ablation Catheter
Study: NCT01409915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagramostim
Description: 5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline -- placebo comparator
Description: subcutaneous injection
Study: NCT02010905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02411279

Intervention type: OTHER
Intervention: Equiped group with telemedicine systems
Study: NCT01745562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: Test product
Study: NCT04933435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaires
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaires
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
Study: NCT03989336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy
Description: Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum chemotherapy
Description: Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
Study: NCT02966132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMD
Description: Interactive video education delivered on a tablet computer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NPA
Study: NCT01352273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162 + RAF265
Study: NCT02179047

Intervention type: PROCEDURE
Intervention: coronary angiography
Description: percutaneous coronary intervention. coronary angiography.

Intervention type: PROCEDURE
Intervention: coronary angiography
Description: percutaneous coronary intervention. coronary angiography.
Study: NCT00961779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion
Study: NCT04136483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
Study: NCT02090777

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Coach
Study: NCT00901615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and R-CHOP
Description: Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
Study: NCT04030676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Two more biopsies in inflammatory zone will be collected.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
Study: NCT00677313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: metreleptin injection
Study: NCT03479008

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Therapeutic Vibration Device
Description: The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
Study: NCT03014271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sources of Strength (SOS) Prevention Program
Description: Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sources of Strength (SOS) Prevention Program
Description: Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
Study: NCT01666912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptive implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive implant
Study: NCT01229215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCFD4514S
Description: Repeating intravitreal injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Repeating sham injection
Study: NCT04403113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured neck and trunk stabilization exercises
Description: Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding and oral motor intervention strategies
Description: Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding and oral motor intervention strategies
Description: Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver training related to feeding
Description: In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver training related to feeding
Description: In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
Study: NCT03619655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT CT
Description: MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT CT
Description: MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT CT
Description: MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET/CT
Description: A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WB-MRI
Description: Whole body MRI exam (total examination time \< 50 minutes)
Study: NCT01877668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Description: Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Description: Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
Study: NCT01792765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: Patient will have intraoperative ultrasound .
Study: NCT03289988

Intervention type: OTHER
Intervention: blood sampling
Description: NK activity and gene panel expression analysis based on blood test (5cc blood sampling)

Intervention type: OTHER
Intervention: blood sampling
Description: NK activity and gene panel expression analysis based on blood test (5cc blood sampling)

Intervention type: OTHER
Intervention: blood sampling
Description: NK activity and gene panel expression analysis based on blood test (5cc blood sampling)

Intervention type: OTHER
Intervention: blood sampling
Description: NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
Study: NCT00731796

Intervention type: DEVICE
Intervention: Functional Outcome Measure
Description: Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.

Intervention type: DEVICE
Intervention: Functional Outcome Measure
Description: Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.

Intervention type: DEVICE
Intervention: Functional Outcome Measure
Description: Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.

Intervention type: DEVICE
Intervention: Functional Outcome Measure
Description: Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
Study: NCT01569945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifen, Ethinyl Estradiol
Description: starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menotropins
Description: Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
Study: NCT02014519

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: A blood sample (2.5 mL) will be collected from all subjects

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Active questioning
Study: NCT01957579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
Study: NCT01473940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00534248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live (Zostavax™)
Description: A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
Study: NCT03620526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
Study: NCT02598739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list for the exercises
Study: NCT00423280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6R-BH4
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6R-BH4
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6R-BH4
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Study: NCT01706835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldoxorubicin